肾透明细胞癌患者血清微小RNA-214和微小RNA-106b的表达及临床意义

发布时间：2018-03-04 03:15

本文选题：肾透明细胞癌　切入点：血清标志物　出处：《新疆医科大学》2017年硕士论文　论文类型：学位论文

【摘要】：目的:检测肾透明细胞癌患者血清中微小RNA-214(miR-214)和微小RNA-106b(miR-106b)手术前后的表达水平,探讨其与临床病理特征间的相互关系及临床应用价值。方法:收集45例2013年7月至2016年4月期间我院泌尿外科新诊断为肾透明细胞癌患者手术前后的血清样本作为实验组。另外收集30例健康体检者的血清样本作为对照组。采用实时荧光定量PCR技术检测各组血清样本中miR-214和miR-106b的表达水平。结果:miR-214在术前、术后1周、术后1月及对照组血清相对表达量分别为6.32(4.87,7.91)、4.96(2.88,9.57)、1.21(0.69,3.17)、1.05(0.44,1.45),而miR-106b血清相对表达量分别为4.10(2.62,9.67)、4.46(1.58,6.76)、0.91(0.62,2.55)、1.28(0.56,1.91)。肾透明细胞癌组术前的血清miR-214相对表达量高于术后1个月及对照组(Z=-4.247,P0.001;Z=-4.330,P0.001),肾透明细胞癌组术后1周的血清miR-214表达量也高于术后1个月及对照组(Z=4.391,P0.001;Z=-4.371,P0.001)。肾透明细胞癌组术前血清miR-214表达量与术后1周比较,以及术后1个月与对照组比较,差异均无统计学意义(Z=-0.998,P=0.318;Z=-0.872,P=0.383)。肾透明细胞癌组术前的血清miR-106b相对表达量高于术后1个月及对照组(Z=-4.206,P0.001;Z=-4.997,P0.001),肾透明细胞癌组术后1周的血清miR-106b相对表达量也高于术后1个月及对照组(Z=3.939,P0.001;Z=-4.132,P0.001)。肾透明细胞癌组术前血清miR-106b相对表达量与术后1周比较,以及术后1个月与对照组比较,差异均无统计学意义(Z=-1.491,P=0.136;Z=-0.377,P=0.706)。根据肾透明细胞癌患者与健康人血清中miRNAs的表达差异,绘制ROC曲线进行分析,得到miR-214的曲线下面积(AUC)=0.858(95%CI:0.756,0.960;P0.05),敏感性为80.0%,特异性为90.0%;miR-106b的曲线下面积(AUC)=0.876(95%CI:0.783,0.968;P0.05),敏感性为86.7%,特异性为80.0%。结论:在肾透明细胞癌患者血清中miR-214和miR-106b的相对表达水平较健康对照组明显升高,在切除肿瘤组织后其表达量均显著下降,利用ROC曲线法分析,其特异性及敏感性均已经达到临床应用价值,是肾透明细胞癌可选的分子标志物。
[Abstract]:Objective: to detect the expression of microRNA-214mmiR-214) and micro-RNA-106bmmiR-106b in serum of patients with clear cell carcinoma of kidney (RCC) before and after operation. To explore the relationship between clinical and pathological features and clinical application value. Methods: 45 patients with renal clear cell carcinoma diagnosed by urology from July 2013 to April 2016 in our hospital were collected as serum samples before and after operation. The serum samples of 30 healthy persons were collected as control group. The expression levels of miR-214 and miR-106b in serum samples of each group were detected by real-time fluorescence quantitative PCR technique. 1 week after operation, The relative expression levels of serum miR-214 in January and control group were 6.32 / 4.87 / 7.91and 4.962.88 / 9.57 respectively, respectively. The relative expression of serum miR-214 in miR-106b was 4.102.62 / 9.67 / 4.461.51.586.766.0.620.62 / 0.62 / 0. 561 respectively. The relative expression of serum miR-214 in clear cell carcinoma group before operation was higher than that in the control group (1 month after operation) and in the control group (P 0.001 Z-4.247g / P 0.001Z-4.330P 0.001), and the relative expression of serum miR-214 in clear cell carcinoma group before operation was higher than that in the control group (P 0.001Z-4.247g P 0.001Z-4.330P 0.001), and in the patients with clear cell carcinoma of kidney, the relative expression of serum miR-214 was higher than that in the control group (P 0.001), and in the patients with renal clear cell carcinoma, the relative expression of serum miR-214 was higher than that in the control group (P 0.001). The expression of serum miR-214 in the latter 1 week was also higher than that in the control group and the control group. The expression of serum miR-214 in the renal clear cell carcinoma group was higher than that in the control group at 1 week after operation, and the expression of serum miR-214 in the renal clear cell carcinoma group was higher than that in the control group at 1 week after operation. And 1 month after operation compared with the control group, There was no significant difference between the two groups. The relative expression of serum miR-106b in clear cell carcinoma group before operation was higher than that in control group at 1 month after operation. The relative expression of serum miR-106b in clear cell carcinoma group was also higher than that in 1 month after operation and in control group. The relative expression of serum miR-106b in clear cell carcinoma group was also higher than that in one month after operation and in the control group. The relative expression of serum miR-106b in the renal clear cell carcinoma group was also higher than that in the control group at 1 week after operation. The relative expression of serum miR-106b in the renal clear cell carcinoma group was higher than that in the control group at 1 month after operation. The relative expression of serum miR-106b in the renal clear cell carcinoma group was compared with that in the first week after operation. Compared with the control group, there was no significant difference between the two groups 1 month after operation. According to the difference of miRNAs expression between the patients with renal clear cell carcinoma and the healthy people, the ROC curve was plotted. Under the curve of miR-214, the area under the curve of miR-214 is 0.858C95 CI: 0.756U 0.960g P0.05, the sensitivity is 80.0and the specific area is 90.0106b. The area under the curve is 0.87695CIW 0.783C: 0.96P0.05, the sensitivity is 86.7, the specificity is 80.00.Conclusion: the relative expression level of miR-214 and miR-106b in the serum of patients with clear cell carcinoma of kidney is obviously higher than that of the healthy control group, and the relative expression of miR-214 and miR-106b in the serum of the patients with clear cell carcinoma of kidney is obviously higher than that of the healthy control group, and the relative expression of miR-214 and miR-106b in the serum of the patients with clear cell carcinoma of kidney is obviously higher than that of the control group. The expression levels of tumor tissues decreased significantly after resection. The specificity and sensitivity of these two markers have reached the clinical application value by ROC curve analysis, which is an optional molecular marker for renal clear cell carcinoma.
【学位授予单位】：新疆医科大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R737.11

【相似文献】